ResQ Pharma, Inc.

Providing global access to "LipidRescue Therapy", a life saving treatment for non-opiate drug overdoses, including: local anesthetics, cocaine, meth, etc...

Company Summary

ResQ Pharma is a research & development company focused on ensuring reliable global access to its lead program, LipidRescue Therapy (LRT). LRT is an antidote for lipophilic/non-opioid drug overdoses. LRT is already widely recommended as an off-label treatment and has a clear and inexpensive path to FDA approval. ResQ has a pre-NDA meeting scheduled with FDA for December 14, 2017 and plans to file the NDA in the first half of next year (2018)

Team

  • Paul Burton, JD, MBA
    Chief Executive Officer

    Over 15 years experience in corporate finance and strategic advisory including with Citigroup Corporate & Investment Bank in NYC and London and as a VP at GE Capital. From 2012 to 2015 served as CFO for Vivacelle Bio, Inc., a company focused on repurposing a lipid emulsion to treat server blood lost (hypovolemic shock) and septic shock. Paul is a former US Army Commissioned Officer and holds both a JD and MBA from the University of Illinois.

  • Christopher Bryant
    Director of Product Development

    Former Chief Scientific Officer and Executive Vice President at Fresenius Kabi, USA

  • Guy Weinberg
    Founder

    Inventor of LipidRescue Therapy (LRT). Professor of Anesthesiology at the University of Illinois College of Medicine at Chicago and staff member at Jesse Brown VA Hospital. Author of over 100 research articles.

  • Mukesh Kumar, PhD, RAC
    Director of Regulatory Affairs

    Formerly Senior Director of Regulatory Affairs at Amarex Clinical Research and prior Staff Scientist at National Institute of Health (NIH).

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free